alexa New Multi-Particle Systems for Colon-Targeted Meloxicam | OMICS International
ISSN: 1920-4159
Journal of Applied Pharmacy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

New Multi-Particle Systems for Colon-Targeted Meloxicam

Eva Navarro Ruiz1*, Covadonga Álvarez Álvarez2, Juan J García Rodriguez1,3, Santiago Torrado Durán1,3, Susana Torrado Durán1,3 and de la Torre Iglesias PM1,3

1Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid 28040, Spain

2Department of Parasitology, Faculty of Pharmacy, Complutense University of Madrid, Madrid 28040, Spain

3Institute of Industrial Pharmacy, Complutense University of Madrid, Madrid 28040, Spain

*Corresponding Author:
Eva Navarro Ruiz
Department of Pharmacy and Pharmaceutical Technology
Faculty of Pharmacy
Complutense University of Madrid
Madrid 28040, Spain
Tel: +346557564196
E-mail: [email protected]

Received date: April 09, 2016; Accepted date: May 13, 2016; Published date: May 19, 2016

Citation: Ruiz EN, Álvarez CA, Rodriguez JJG, Durán ST, Durán ST, et al. (2016) New Multi-Particle Systems for Colon-Targeted Meloxicam. J App Pharm 8:221. doi:10.4172/1920-4159.1000221

Copyright: © 2016 Ruiz EN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Applied Pharmacy

Abstract

Meloxicam (MLX) is a non-steroidal anti-inflammatory drug (NSAIDs) from the Oxicam family. This group of NSAIDs has been highly used in the treatment of rheumatoid arthritis and post-operative inflammation and is known as good antioxidants. Recently, their activity in chemoprevention, chemo-suppression, UV-sensitization and UVprotection was also identified. MLX has been described as a COX-2 selective inhibitor. Its use has some advantages regarding to its selectivity, namely, less adverse effects as gastrointestinal aggression and anticlotting activity. As MLX is better absorbed in colon and its properties against colon cancer and colonic inflammatory diseases are being studied, it is interesting to investigate a new MLX formulation for colonic delivery. We are studying the solubility and the dissolution of different combined formulations at pH 1.2, 6.8 and 7.4 to mimic their absorbance in the colon. These formulations are composed by different excipients that provide pH and time-dependent deliveries such as cellulose (Metolose®) and methacrylic acid esters with quaternary ammonium groups (EUDRAGIT® RS 30D, EUDRAGIT® FS 30D and EUDRAGIT® NM 30D).

Keywords

Meloxicam; Colon targeting; Granulated

Introduction

Meloxicam (MLX) is a non esteroidic anti-inflamatory (AINE) from the Oxicam family [1-11]. This group of AINEs is frequently used in the treatment of rheumatic arthritis and post operatory inflammations; besides it is known as a good antioxidant. Recently, it has been found to have utility in chemoprevention, chemosupression and UV protection. The MLX is a selective inhibitor for COX–2 [3,4,7,11-14], with high selectivity and fewer gastrointestinal side effects. Because this drug is well absorbed in the colonic region, they are studying their properties against colon cancer and diseases of this area, so it is interesting to investigate new formulations of colonic delivery of this active substance [1,3,4,13-17].

Materials and Methods

Materials

Meloxicam (MLX, Fagron, Barcelona, Spain); Methylcellulose (MC, Metolose® 90 SH 100, Shin-Etsu Chemical Co., Ltd., Tokyo, Japan); aqueous dispersion of a copolymer of ethyl acrylate and methyl methacrylate (EUDRAGIT® FS 30D and Eudragit® NM 30D, Evonik Röhm gift, D); alpha-lactose monohydrate (L, Fagron, Barcelona, Spain). All products of pharmaceutical grade or higher.

Preparation of formulations

The studied MLX was granulated with lactose and three types of Eudragit®: RS, FS and NM; some granules containing 5% of cellulose (Metolose® 90 SH 100). Different granulates (Table 1) were prepared with different proportions of these components and those granules with diameters between 0.350 and 0.355 mm selected.

FORMULATIONS MLX (%) L (%) MC (%) EUDRAGIT® RS EUDRAGIT® FS EUDRAGIT® NM
RS 17.5 53.0 5.0 30.0 0 0
FS 17.5 53.0 5.0 0 30.0 0
NM 17.5 53.0 5.0 0 0 30.0
RS+FS 17.5 53.0 5.0 15.0 15.0 0
NM+FS 17.5 53.0 5.0 0 15.0 15.0
CRS 17.5 48.0 5.0 30.0 0 0
CFS 17.5 48.0 5.0 0 30.0 0
CNM 17.5 48.0 5.0 0 0 30.0
CRS+CFS 17.5 48.0 5.0 15.0 15.0 0
CNM+CFS 17.5 48.0 5.0 0 15.0 15.0

Table 1: Composition of formulations.

In vitro release

The granules were subjected to test dissolution rate in dissolution apparatus containing in their buckets 10 mg or equivalent MLX granulated with 500 ml of pH 1.2, 37°C and 50 rpm, for 2 h, after that the medium was completed with 167 ml from buffer to reach pH 6.8, 37°C and 50 rpm for 3 h, then 5 ml of NaOH 2 M was added to obtain pH 7.4, 37°C and 50 rpm. The experiment lasted 24 h. Aliquots were taken every hour the first two hours and then every half hour until 8 h, taking one last aliquot at 24 h. The samples were measured undiluted on the spectrophotometer at 364 nm wavelength. Each determination at each time point was performed in triplicate and the error bars on the graphs represented the standard deviation.

Results and Discussion

The rate of dissolution test noted that the best results (Figure 1) obtained was the CNM granulate containing Eudragit® NM and 5% cellulose, which releases the 94.52% if the active ingredient at 8h, resulting the most balanced release profile. Granulate FS was the slowest, releasing only the 24.52% of the MLX at t=8 h.

applied-pharmacy-Release-profiles

Figure 1: Release profiles at 37°C of several products in SCF: CNM (-•-); NM (-•-); CRS (-•-); RS (-•-); NM+ FS (-•-); CNM+CFS (-•-); FS (- •-); CFS (-•-); RS+FS (-•-) and CRS+CFS (-•-).

As an intermediate granulate we chose CFS, which gives a 56.69% after 8 h.

It was observed that, by adding cellulose (Metolose® 90 SH 100) the solubility coefficient is increased because it facilitates the disintegration of the formulation.

Conclusion

We have developed a new colonic formulation of multiparticulate MLX, easy and economical to produce industrially. For subsequent studies, we will select the granule with higher percentage of release (CNM) after 8h, the one with lower percentage (FS) and the one that was intermediate (CFS) to perform in vivo assays in mice and other analytical studies to corroborate the results.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8054
  • [From(publication date):
    July-2016 - Dec 11, 2017]
  • Breakdown by view type
  • HTML page views : 7992
  • PDF downloads : 62
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version